在帕金森病中对神经元和质细胞损伤的α-synuclein贡献
Kamil Saramowicz1, Natalia Siwecka1, Grzegorz Galita1
1Department of Clinical Chemistry and Biochemistry, Medical University of Lodz, 92-215 Lodz, Poland.
International journal of molecular sciences
|January 11, 2024
概括
帕金森病涉及α-synuclein (αSyn) 蛋白质聚合物损害神经元和神经细胞. 了解 αSyn 的理解
科学领域:
- 神经科学是一个神经科学.
- 细胞生物学 细胞生物学
- 神经退行性疾病 神经退行性疾病
背景情况:
- 帕金森病 (PD) 的特征是多巴胺能神经元损失和α-synuclein (αSyn) 聚合.
- αSyn病理影响神经元和质细胞 (小质细胞和星球细胞),影响疾病的进展.
- 精确的细胞功能,聚合机制和αSyn的损伤诱导仍然不完全理解.
研究的目的:
- 为提供对最近关于α-synuclein (αSyn) 的研究的概述.
- 强调αSyn的多面性及其对神经元和质细胞损伤的影响.
- 探索αSyn,神经元和质细胞之间的相互作用,以寻找潜在的治疗策略.
主要方法:
- 对最近的科学文献的审查,重点是帕金森病中的α-synuclein (αSyn).
- 对研究αSyn在神经元和质细胞功能和损伤中的作用的分析.
- 综合与αSyn聚合,细胞过程中断和神经炎症相关的发现.
主要成果:
- 阿尔法-同核素 (αSyn) 聚合会破坏突触功能,线粒体完整性和蛋白质稳定,导致神经元死亡.
- 质细胞内部化αSyn,作为神经保护性清除剂或促进神经炎症和PD进展.
- 最近的进展允许分子诊断和向治疗的发展,但αSyn的全部影响仍在调查中.
结论:
- 了解αSyn,神经元和质细胞之间的复杂相互作用对于阐明PD启动和进展至关重要.
- 对αSyn多面性质的进一步研究可能会导致帕金森病的新有效治疗策略.
- 针对αSyn对神经元和质细胞的影响,为未来的PD治疗提供了有希望的途径.
相关概念视频
Parkinson's Disease: Overview
551
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
551
Neural Regulation
39.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.4K
Parkinson's Disease: Treatment
272
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
272
Alzheimer's Disease: Overview
490
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
490


